ClinicalTrials.gg
RecruitingNCT06630806Updated Mar 25, 2026

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

A Phase 1 interventional study of SAR446523 in Plasma Cell Myeloma Refractory, sponsored by Sanofi. Recruiting at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 39 studies in Multiple Myeloma by Sanofi — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · Sanofi.

Planned enrollment
13th of 34
87 · median 56
Started
2024
the only one that year
Phase 1
10 of 39
1 open now
Registered
39th of 39
by date

Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 13th largest by planned enrollment of the 34 interventional ones that give a count, is the only one that started in 2024, is one of 10 in phase 1, and was the 39th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 39 studies in Multiple Myeloma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Multiple Myeloma by Sanofi, or all of them as a file.
02

Study summary

This is a first-in-human study of SAR446523 conducted in patients with RRMM.

The study consists of two parts:

Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the maximum administered dose (MAD), maximum tolerated dose (MTD), and recommended dose range (RDR) of 2 dose regimens which will be tested in the dose optimization part.

Dose optimization (Part B): In this part, participants will be randomly assigned in a 1:1 ratio using interactive response technology (IRT) to either one of the chosen dose regimens of SAR446523 (determined from data coming from Part A), to determine the optimal dose as the recommended phase 2 dose (RP2D) of SAR446523.

Read the detailed description

The study will be considered ongoing until the last participant last visit has occurred. Participants will be allowed to continue therapy until disease progression, unacceptable AEs, participant or Investigator's request to discontinue treatment.

03

Conditions studied

  • Plasma Cell Myeloma Refractory

Browse trials for

Keywords

  • anti-GPRC5D NK cell targeting therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a documented diagnosis of multiple myeloma (MM) with .
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Dose escalation (Part A)

  • Participants must have received at least 3 prior lines of antimyeloma therapy, and must be either to the above therapies, or are intolerant to them.
  • Note: In Part A, prior exposure to anti g-protein-coupled receptor, class c, group 5, member d (GPRC5D) therapy and anti B-cell maturation antigen (BCMA) therapy is allowed.

Dose optimization (Part B)

  • Participants must have received at least 3 prior lines of antimyeloma therapy and be either relapsed or refractory to immunomodulator (IMiD), proteasome inhibitor (PI), anti CD38 monoclonal antibody (mAb), and anti BCMA targeting agent or are intolerant to them.
  • Note: In Part B, prior exposure to antiGPRC5D therapy is not allowed.

Exclusion criteria

Exclusion Criteria:

-Participants are excluded from the study if any of the following criteria apply: performance status (ECOG PS) of 2 or greater.

  • Primary systemic and localized amyloid light chain (AL) amyloidosis, active polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome, active plasma cell leukemia. Participants with central nervous system involvement or with clinical signs of meningeal involvement of multiple myeloma.
  • Systemic antimyeloma treatment within 14 days before the first study treatment administration.
  • Prior treatment with natural killer (NK)-cell engaging therapy (such as monoclonal antibody with antibody-dependent cellular cytotoxicity as primary mechanism of action) within 90 days of the first study treatment administration.
  • Inadequate organ and marrow function.
  • Participants with significant concomitant illness.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    Part A (Dose escalation)

    Participants will receive SAR446523

    Drug: SAR446523

  • Experimental
    Part B Dose-1 (Dose optimization)

    Participants will receive SAR446523 Dose-1

    Drug: SAR446523

  • Experimental
    Part B Dose-2 (Dose optimization)

    Participants will receive SAR446523 Dose-2

    Drug: SAR446523

Interventions

  • DrugSAR446523

    Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs)- Dose escalation (Part A)

    The incidence of DLTs will be evaluated using NCI CTCAE version 5.0 criteria.

    Time frame: Cycle 1 (28 days)

  2. Overall response rate (ORR) - Dose optimization (Part B)

    ORR is defined as the proportion of participants with sCR, CR, VGPR, and PR assessed as per Investigator according to the 2016 IMWG response criteria.

    Time frame: 24 months after the Last Participant In (LPI)

Secondary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs), injection related reactions (IRRs), injection site reactions (ISRs), serious adverse events (SAEs), adverse event of special interests (AESIs)

    Measured as per NCI CTCAE v 5.0

    Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 5 years

  2. Change from baseline in laboratory abnormalities

    Measured as per NCI CTCAE v 5.0.

    Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 5 years

  3. ORR- Dose escalation (Part A)

    ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) assessed as per Investigator according to the 2016 International Myeloma Working Group (IMWG) response criteria.

    Time frame: 24 months after the Last Participant In (LPI)

  4. VGPR or better rate

    VGPR or better rate defined as the proportion of participants with sCR, CR, and VGPR assessed as per Investigator according to the 2016 IMWG response criteria.

    Time frame: 24 months after the Last Participant In (LPI)

  5. Clinical benefit rate (CBR)

    CBR defined as the rate of participants with confirmed sCR, CR, VGPR, or PR at any time or minimal response (MR) of at least 6 months from the first IMP administration determined per 2016 IMWG response criteria.

    Time frame: 24 months after the Last Participant In (LPI)

  6. Duration of response (DoR)

    DoR defined as the time from the date of the first response (PR or better) to the date of first documentation of progressive disease (PD) as defined in the 2016 IMWG response criteria, or date of death, whichever occurs first.

    Time frame: 24 months after the Last Participant In (LPI)

  7. Time to response (TTR)

    TTR defined as the time from the first administration of study IMP to the date of first response (PR or better) that is subsequently confirmed.

    Time frame: 24 months after the Last Participant In (LPI)

  8. Progression free survival (PFS)

    PFS defined as the time interval from the date of first administration of study IMP to the date of first documentation of PD per 2016 IMWG criteria assessed by study Investigator, or date of death from any cause, whichever comes first.

    Time frame: 24 months after the Last Participant In (LPI)

  9. Minimal residual disease (MRD) status negativity

    MRD status negative by nextgeneration sequencing (NGS) in bone marrow of participants with a response of CR (or VGPR in case of suspected interference).

    Time frame: 24 months after the Last Participant In (LPI)

  10. Number of participants with symptomatic AEs -Part B

    The incidence and evaluation of symptomatic AEs from participants' perspective will be measured by using specific items from National Cancer Institute (NCI) patient-reported outcome (PRO) common terminology criteria for adverse events (CTCAE) library.

    Time frame: From Cycle 1 Day 1 to 30 days after the date of the last study treatment administration i.e., approximately 5 years

  11. Change from baseline in overall side effect bother as measured by the Functional Assessment of Cancer Therapy item 5 (FACT-GP5)- Part B

    The FACT GP5 is an assessment focused on the overall side effect impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5 point Likert type scale recalling the past 7 days. Higher scores indicate a higher degree of side effect bother.

    Time frame: From Cycle 1 Day 1 to 30 days after the date of the last study treatment administration i.e., approximately 5 years

  12. Maximum observed concentration (Cmax)

    To characterize the pharmacokinetics (PK) of SAR446523.

    Time frame: Multiple timepoints from Cycle 1 Day 1 to Cycle 1 Day 8 (cycle 1=28 days)

  13. First time to reach Cmax (tmax)

    To characterize the PK of SAR446523.

    Time frame: Multiple timepoints from Cycle 1 Day 1 to Cycle 1 Day 8 (cycle 1=28 days)

  14. Area under the concentration versus time curve calculated from 0 to 168 hours (AUC0-168h)

    To characterize the PK of SAR446523.

    Time frame: Multiple timepoints from Cycle 1 Day 1 to Cycle 1 Day 8 (cycle 1=28 days)

  15. Proportion of participants with presence of anti-drug antibody (ADA) against SAR446523.

    To evaluate potential immunogenicity.

    Time frame: From Cycle 1 Day 1 to 30 days after the date of the last study treatment administration i.e., approximately 5 years

07

Study locations

19 of 19 sites recruiting
  • Mayo Clinic in Arizona - Phoenix- Site Number : 8400005
    Phoenix, Arizona 85054, United States
    Recruiting
  • Mayo Clinic in Florida- Site Number : 8400003
    Jacksonville, Florida 32224, United States
    Recruiting
  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400004
    Rochester, Minnesota 55905, United States
    Recruiting
  • Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400001
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Thomas Jefferson University Hospital- Site Number : 8400002
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Investigational Site Number : 0360001
    Wollongong, New South Wales 2500, Australia
    Recruiting
  • Investigational Site Number : 0360002
    Melbourne, Victoria 3065, Australia
    Recruiting
  • Investigational Site Number : 1240005
    Vancouver, British Columbia V5Z 1L3, Canada
    Recruiting
  • Investigational Site Number : 1240001
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Investigational Site Number : 1240002
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
  • Investigational Site Number : 2500002
    Lille, 59037, France
    Recruiting
  • Investigational Site Number : 2500001
    Nantes, 44093, France
    Recruiting
  • Investigational Site Number : 3760001
    Tel Aviv, Malopolskie 6423906, Israel
    Recruiting
  • Investigational Site Number : 3760004
    Haifa, 3109601, Israel
    Recruiting
  • Investigational Site Number : 3760002
    Jerusalem, 9112001, Israel
    Recruiting
  • Investigational Site Number : 3800002
    Torette, Ancona 60020, Italy
    Recruiting
  • Investigational Site Number : 3800001
    Rozzano, Milano 20089, Italy
    Recruiting
  • Investigational Site Number : 7240002
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
  • Investigational Site Number : 7240001
    Madrid, 28040, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2031, 78 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 78 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2024
First posted
Oct 8, 2024
StartActual
Oct 30, 2024
Primary completionEst.
May 16, 2031
CompletionEst.
May 16, 2031
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630806
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Oct 30, 2024
Primary completion
May 16, 2031 (estimated)
Completion
May 16, 2031 (estimated)
Last update
Mar 25, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion